Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Healthtrust
Chinese Patent Office
Deloitte
AstraZeneca
Julphar
UBS
Farmers Insurance
Merck

Generated: April 21, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 050818

« Back to Dashboard

NDA 050818 describes TOBRADEX ST, which is a drug marketed by Novartis Pharms Corp and is included in one NDA. It is available from one supplier. There are three patents protecting this drug. Additional details are available on the TOBRADEX ST profile page.

The generic ingredient in TOBRADEX ST is dexamethasone; tobramycin. There are thirty-nine drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the dexamethasone; tobramycin profile page.
Summary for 050818
Tradename:TOBRADEX ST
Applicant:Novartis Pharms Corp
Ingredient:dexamethasone; tobramycin
Patents:3
Formulation / Manufacturing:see details
Pharmacology for NDA: 050818
Suppliers and Packaging for NDA: 050818
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
TOBRADEX ST dexamethasone; tobramycin SUSPENSION/DROPS;OPHTHALMIC 050818 NDA Alcon Laboratories, Inc. 0065-0652 N 0065-0652-05
TOBRADEX ST dexamethasone; tobramycin SUSPENSION/DROPS;OPHTHALMIC 050818 NDA Alcon Laboratories, Inc. 0065-0652 N 0065-0652-01

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:SUSPENSION/DROPS;OPHTHALMICStrength0.05%;0.3%
Approval Date:Feb 13, 2009TE:RLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:Aug 3, 2028Product Flag?YSubstance Flag?Delist Request?
Patented Use:USE OF A COMBINATION OF TOBRAMYCIN AND DEXAMETHASONE TO TREAT OCULAR INFLAMMATION WHERE AN INFECTION OR RISK OF INFECTION EXISTS
Patent:➤ Try a Free TrialPatent Expiration:Dec 19, 2027Product Flag?YSubstance Flag?Delist Request?
Patented Use:USE OF A COMBINATION OF TOBRAMYCIN AND DEXAMETHASONE TO TREAT OCULAR INFLAMMATION WHERE AN INFECTION OR RISK OF INFECTION EXISTS
Patent:➤ Try a Free TrialPatent Expiration:Dec 19, 2027Product Flag?YSubstance Flag?Delist Request?

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Julphar
Federal Trade Commission
Cipla
Covington
McKinsey
McKesson
Healthtrust
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.